Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates

被引：4

作者：

Suraya, Ratoe ^{[1
]}

Tachihara, Motoko ^{[1
]}

Nagano, Tatsuya ^{[1
]}

Nishimura, Yoshihiro ^{[1
]}

Kobayashi, Kazuyuki ^{[1
]}

机构：

[1] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Resp Med, Kobe, Hyogo, Japan

来源：

CANCER MANAGEMENT AND RESEARCH | 2022年 / 14卷

关键词：

non-small cell lung cancer; immune checkpoint inhibitors; PD-1; PD-L1; CTLA-4; OPEN-LABEL; 1ST-LINE NIVOLUMAB; IMMUNE-SYSTEM; FOLLOW-UP; PD-1; PEMBROLIZUMAB; CHEMOTHERAPY; ATEZOLIZUMAB; MULTICENTER; PHASE-3;

D O I：

10.2147/CMAR.S366738

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Non-small-cell lung cancer (NSCLC) is a major health burden, and novel therapeutic options are needed to help solve this problem. One such option is immunotherapy, which targets immune checkpoint molecules that inhibit cancer cells, decreasing immune system activation, for example, immunotherapies target PD-1, its ligand PD-L1, and CTLA-4. There have been major advances in the development of agents that inhibit these molecules, called immune checkpoint inhibitors, and several of them are already approved for usage in NSCLC patients, especially in advanced stages. In this review, the reasons why immune checkpoint inhibitors could be beneficial and the clinical results of studies using these drugs for advanced or recurrent NSCLC patients are discussed, as is the safety profile of the drugs.

引用

页码：2079 / 2090

页数：12

共 60 条

[1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[2] Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis [J].

Antonia, Scott J. ;

Borghaei, Hossein ;

Ramalingam, Suresh S. ;

Horn, Leora ;

De Castro Carpeno, Javier ;

Pluzanski, Adam ;

Burgio, Marco A. ;

Garassino, Marina ;

Chow, Laura Q. M. ;

Gettinger, Scott ;

Crino, Lucio ;

Planchard, David ;

Butts, Charles ;

Drilon, Alexander ;

Wojcik-Tomaszewska, Joanna ;

Otterson, Gregory A. ;

Agrawal, Shruti ;

Li, Ang ;

Penrod, John R. ;

Brahmer, Julie .

LANCET ONCOLOGY, 2019, 20 (10) :1395-1408

[3] Lung Cancer 2020 Epidemiology, Etiology, and Prevention [J].

Bade, Brett C. ;

Dela Cruz, Charles S. .

CLINICS IN CHEST MEDICINE, 2020, 41 (01) :1-+

[4] Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm [J].

Banna, Giuseppe Luigi ;

Cantale, Ornella ;

Bersanelli, Melissa ;

Del Re, Marzia ;

Friedlaender, Alex ;

Cortellini, Alessio ;

Addeo, Alfredo .

ONCOLOGY REVIEWS, 2020, 14 (02) :135-143

[5] Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study [J].

Barlesi, Fabrice ;

Vansteenkiste, Johan ;

Spigel, David ;

Ishii, Hidenobu ;

Garassino, Marina ;

de Marinis, Filippo ;

Ozguroglu, Mustafa ;

Szczesna, Aleksandra ;

Polychronis, Andreas ;

Uslu, Ruchan ;

Krzakowski, Maciej ;

Lee, Jong-Seok ;

Calabro, Luana ;

Frontera, Osvaldo Aren ;

Ellers-Lenz, Barbara ;

Bajars, Marcis ;

Ruisi, Mary ;

Park, Keunchil .

LANCET ONCOLOGY, 2018, 19 (11) :1468-1479

[6] A review of guidelines for lung cancer [J].

Bironzo, Paolo ;

Di Maio, Massimo .

JOURNAL OF THORACIC DISEASE, 2018, 10 :S1556-S1563

[7] Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study [J].

Boyer, Michael ;

Sendur, Mehmet A. N. ;

Rodriguez-Abreu, Delvys ;

Park, Keunchil ;

Lee, Dae Ho ;

Cicin, Irfan ;

Yumuk, Perran Fulden ;

Orlandi, Francisco J. ;

Leal, Ticiana A. ;

Molinier, Olivier ;

Soparattanapaisarn, Nopadol ;

Langleben, Adrian ;

Califano, Raffaele ;

Medgyasszay, Balazs ;

Hsia, Te-Chun ;

Otterson, Gregory A. ;

Xu, Lu ;

Piperdi, Bilal ;

Samkari, Ayman ;

Reck, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) :2327-+

[8] CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy [J].

Brunner-Weinzierl, Monika C. ;

Rudd, Christopher E. .

FRONTIERS IN IMMUNOLOGY, 2018, 9

[9] CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition [J].

Buchbinder, Elizabeth I. ;

Desai, Anupam .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01) :98-106

[10] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

← 1 2 3 4 5 6 →